CASIMERSEN (SRP-4045), GOLODIRSEN (SRP-4053), 0,9% sodium chloride
4045-301
Phase 3 small_molecule active
Quick answer
CASIMERSEN (SRP-4045), GOLODIRSEN (SRP-4053), 0,9% sodium chloride for Patients with Duchenne Muscular Dystrophy Amenable to Exon 45 or 53 Skipping. is a Phase 3 program (small_molecule) at Sarepta Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Sarepta Therapeutics
- Indication
- Patients with Duchenne Muscular Dystrophy Amenable to Exon 45 or 53 Skipping.
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active